Delving into the Latest Updates on Propiverine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Propiverine, Propiverine Hydeochloride, Propiverine hydrochloride (JP17)

+ [10]

Target

mAChRs

Action

antagonists

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Urogenital Diseases

Active Indication

Neurogenic detrusor overactivityUrinary Bladder, OveractiveUrinary Incontinence

Inactive Indication

syndrome; salt-losing, adrenogenital syndromeUrinary Bladder, NeurogenicUrinary Incontinence, Urge

Originator Organization

APOGEPHA Arzneimittel GmbH

Active Organization

Taiho Pharmaceutical Co., Ltd.

APOGEPHA Arzneimittel GmbH

Duchesnay, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (02 Apr 1993),

Urinary Incontinence

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H30ClNO3

InChIKeyKFUJMHHNLGCTIJ-UHFFFAOYSA-N

CAS Registry54556-98-8

View All Structures (2)

A total of 40 volunteers women with a diagnosis of interstitial cystitis. Their ages ranged from 25 to 40 years old; their body mass index was > 30 kg/m2 and were randomly assigned to a group (A) received interferential current at the lower abdomen, and also received traditional medicine or group (B) received traditional medicine for 8 successive weeks. Both of the groups received the treatment program for 8 successive weeks. Assessment of pain perception and disability level for all patients in both groups (A&B) were done through Visual analogue scale, O'Leary-Sant Symptom Index or Interstitial Cystitis Index (ICSI) and blood cortisol concentration were done before and after the treatment program.

Start Date01 Jan 2019

Sponsor / Collaborator

Cairo University

NCT03602508

/ CompletedNot Applicable

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.
This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Start Date20 Jul 2018

Sponsor / Collaborator

Astellas Pharma Singapore Pte Ltd.

NCT03572231

/ CompletedNot Applicable

A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China

The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice.
This study will also evaluate effectiveness of OAB therapies in routine clinical practice; identify factors associated with effectiveness and persistence of pharmacologic therapies in OAB participants; evaluate the Quality of Life (QoL) and treatment satisfaction of OAB therapies; as well as evaluate health care resource utilization (HCRU) and understand adverse events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) associated with OAB therapies.

Start Date19 Jul 2018

Sponsor / Collaborator

Astellas Pharma Singapore Pte Ltd.

100 Clinical Results associated with Propiverine Hydrochloride

Login to view more data

100 Translational Medicine associated with Propiverine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Propiverine Hydrochloride

Login to view more data

1,416

Literatures (Medical) associated with Propiverine Hydrochloride

01 Mar 2025·Molecular Biotechnology

ADME Study, Molecular Docking, Elucidating the Selectivities and the Mechanism of [4 + 2] Cycloaddition Reaction Between (E)-N ((dimethylamino)methylene)benzothioamide and (S)-3-acryloyl-4-phenyloxazolidin-2-one

Article

Author: Atif, Mhamed ; Bahkali, Ali H ; Zeroual, Abdellah ; Wang, Shifa ; Tounsi, Abdessamad ; Barhoumi, Ali ; Paray, Bilal Ahamad ; El Idrissi, Mohammed ; Chafi, Mohammed ; Syed, Asad

The molecular electron density theory (MEDT) was employed to examine the [4 + 2] cycloaddition reaction between (E)-N-((dimethylamino)methylene)benzothioamide (1) and (S)-3-acryloyl-4-phenyloxazolidin-2-one (2) at the B3LYP/6-311++G(d,p) design level. Parr functions and energy studies clearly show that this reaction is regio- and stereoselective, in perfect agreement with experimental results. By evaluating the chemical mechanism in terms of bond evolution theory (BET) and electron localization function (ELF), which divulges a variety of variations in the electron density along the reaction path, a single-step mechanism with highly asynchronous transition states structures was revealed. Additionally, we conducted a docking study on compounds P1, P2, P3, and P4 in the SARS-CoV-2 main protease (6LU7) in comparison to Nirmatrelvir. Our findings provide confirmation that product P4 may serve as a potent antiviral drug.

02 Jan 2025·Expert Opinion on Drug Safety

Risk of drug-induced delirium in older patients- a pharmacovigilance study of FDA adverse event reporting system database

Article

Author: Cui, Yimin ; Li, Jiayu ; Zhou, Ying ; Wan, Liyan ; Jia, Boying ; Zhou, Shuang

BACKGROUNDDrug-induced delirium is known risk factors associated with increased morbidity and mortality in older patients. The objective was to evaluate the risk of drug-related delirium in older patients based on the FDA Adverse Event Reporting System (FAERS).RESEARCH DESIGN AND METHODSDelirium reports in older patients (age ≥65) extracted from the FAERS database using Open Vigil 2.1. The reported odds ratio and the proportional reported ratio were calculated to detect the adverse reaction signal of delirium. Combined with published evidence, suspected drugs were categorized as known, possible, or new potential delirium-risk-increasing drugs.RESULTSOf the 130,885 reports (including 28,850 delirium events and 1,857 drugs) analyzed for this study, 314 positive signal drugs were detected. Positive signal drugs are mainly concentrated on the drug of nervous system, cardiovascular system , alimentary tract and metabolism and anti-infectives for systemic use. Of the positive signal drugs, 26.11% (82/314) were known delirium-risk increasing drugs, 44.90% (141/314) were possible and 28.98% (91/314) were new potential.CONCLUSIONDrug-induced delirium risk is prevalent in older patients, according to the FAERS. The risk level of drug-induced delirium should be taken into account to optimize drug therapy in clinical practice.

01 Jan 2025·Journal of Assisted Reproduction and Genetics

Exogenous progesterone rescue in patients with low mid-luteal serum progesterone levels undergoing true natural vitrified-warmed blastocyst transfer

Article

Author: Humaidan, Peter ; Yarali, Hakan ; Erden, Murat ; Ozbek, Irem Yarali ; Esteves, Sandro C. ; Ince, Onur ; Esteves, Sandro C ; Mumusoglu, Sezcan

PURPOSETo explore whether a 25 mg subcutaneous progesterone daily rescue daily improves the reproductive outcomes in patients with low serum progesterone (P₄) levels (7-10 ng/mL), measured one day before true natural cycle (t-NC) frozen embryo transfer (FET).METHODSA cohort study of 192 women undergoing t-NC warmed blastocyst transfer. Patients were stratified into three different groups based on serum P₄ levels on the FET-1 day: patients who had serum P₄ levels of 7-10 ng/mL and underwent rescue progesterone administration (rescue group), patients with serum P₄ levels of 7-10 ng/mL without progesterone administration (non-rescue group), and patients with serum P₄ > 10 ng/mL on FET-1 day (control group). The primary outcome was possible differences in live birth rate (LBR) between groups.RESULTSThe LBRs for the serum P₄ 7-10 ng/mL without rescue, 7-10 ng/mL with rescue, and > 10 ng/mL (control) groups were 41%, 46%, and 52%, respectively (p = 0.61). The estimated adjusted probability of live birth for serum P₄ 7-10 ng/mL without rescue, 7-10 ng/mL with rescue, and > 10 ng/mL (control) groups were also comparable: 43.5% (95% CI, 20.0-70.4%), 49.8% (95% CI, 28.1-71.6%), and 57.4% (95% CI, 44.0-69.8%), respectively.CONCLUSIONSerum P₄ levels higher than 7 ng/mL seem to secure LBRs in patients undergoing t-NC FET. A rescue policy consisting of a daily subcutaneous 25 mg progesterone dose in patients with serum P₄ levels 7-10 ng/mL does not further enhance LBRs when compared to those patients with similar serum P₄ levels without rescue.

100 Deals associated with Propiverine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01007	Propiverine Hydrochloride	G04BD06	DB12278

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neurogenic detrusor overactivity	Canada	Duchesnay, Inc.	05 Jan 2017
Urinary Bladder, Overactive	Canada	Duchesnay, Inc.	05 Jan 2017
Urinary Incontinence	Japan	Taiho Pharmaceutical Co., Ltd.	02 Apr 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Incontinence, Urge	Phase 1	China	APOGEPHA Arzneimittel GmbH	01 Jan 2010
Urinary Bladder, Neurogenic	Phase 1	Romania	APOGEPHA Arzneimittel GmbH	01 Dec 2004
Urinary Bladder, Neurogenic	Phase 1	Germany	APOGEPHA Arzneimittel GmbH	01 Dec 2004
Urinary Bladder, Neurogenic	Phase 1	Austria	APOGEPHA Arzneimittel GmbH	01 Dec 2004
syndrome; salt-losing, adrenogenital syndrome	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Oct 2004
Neurogenic detrusor overactivity	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004
Urinary Bladder, Overactive	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004
Urinary Incontinence	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02294396 (CTgov)	Phase 4	Urinary Bladder, Overactive	649	Mirabegron tablet+Solifenacin tablet (Mirabegron + Solifenacin)	wbgoowmacr(vutiizxhpj) = mhdufzbhet qbsoohqfzm (zcijrxmjns, nsnbctizwh - gohbkiefur) View more	-	24 Dec 2018
				Mirabegron tablet+Propiverine tablet (Mirabegron + Propiverine)	wbgoowmacr(vutiizxhpj) = dsutvmwgfr qbsoohqfzm (zcijrxmjns, rgygxcffeq - uqpvgztupb) View more
NCT01512004 (Pubmed \| BJU Int) Manual	Phase 3	Urinary Bladder, Overactive	324	propiverine	xlgeamxhcd(kdiynekmji) = qeiykoyntw ywqggjcoax (eogyghdczp, 4.1) View more	Non-inferior	01 Jan 2017
				tolterodine	xlgeamxhcd(kdiynekmji) = adzodijwfr ywqggjcoax (eogyghdczp, 5.1) View more
NCT00903045 (Pubmed \| BJU Int)	Phase 4	Urinary Bladder, Overactive	264	Propiverine 20 mg	cyugtklwdg(ckeckarxlr) = kwmwseofqh dwahmmhxeq (xyskwoeuml )	Positive	01 Jun 2010
				Placebo	cyugtklwdg(ckeckarxlr) = lktzoymbiu dwahmmhxeq (xyskwoeuml )
NCT00795925 (Pubmed \| Clin Pharmacokinet)	Phase 2	Urinary Bladder, Overactive	25	Propiverine 5 mg	bjibzbdens(bvrdfwcozr) = Most of the adverse events that were probably or possibly drug related were reported for patients in the high-dose group (>0.45 mg/kg) vskpmvmkur (orzpzqpmuk )	-	01 May 2010
				Propiverine 10 mg
NCT00603343 (Pubmed \| Eur Urol)	Phase 3	Urinary Incontinence \| Urinary Bladder, Overactive	171	Propiverine	omhygaasld(dkcybqcwli) = cvbbemnsxi kejidlsvle (gqsdjorgcg ) View more	Positive	01 Mar 2009
				Placebo	omhygaasld(dkcybqcwli) = tdrcimrgdc kejidlsvle (gqsdjorgcg ) View more